11196 related articles for article (PubMed ID: 11473731)
1. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
[TBL] [Abstract][Full Text] [Related]
2. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
4. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
5. The molecular targets of antitumor 2'-deoxycytidine analogues.
Obata T; Endo Y; Murata D; Sakamoto K; Sasaki T
Curr Drug Targets; 2003 May; 4(4):305-13. PubMed ID: 12699351
[TBL] [Abstract][Full Text] [Related]
6. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
Balzarini J; De Clercq E
Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
8. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
[TBL] [Abstract][Full Text] [Related]
9. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay.
Kawasaki H; Shindou K; Higashigawa M; Cao DC; Hori H; Ido M; Sakurai M
Leuk Res; 1996 Aug; 20(8):677-82. PubMed ID: 8913321
[TBL] [Abstract][Full Text] [Related]
10. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
[TBL] [Abstract][Full Text] [Related]
11. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
12. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H
Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801
[TBL] [Abstract][Full Text] [Related]
13. Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine.
Zhang M; Endo Y; Sasaki T
Int J Oncol; 1999 Mar; 14(3):543-9. PubMed ID: 10024689
[TBL] [Abstract][Full Text] [Related]
14. [Nucleoside kinases and new types of antitumor nucleosides].
Matsuda A
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1594-9. PubMed ID: 9309159
[TBL] [Abstract][Full Text] [Related]
15. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
16. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
17. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
18. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.
Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR
Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
20. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Bhalla K; Holladay C; Lutzky J; Ibrado AM; Bullock G; Jasiok M; Singh S
Gynecol Oncol; 1992 Apr; 45(1):32-9. PubMed ID: 1601333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]